Doctors at the Oklahoma Medical Research Foundation are celebrating what could become a breakthrough in brain cancer treatment.
OKN-007
FDA grants designations for OMRF brain tumor drug
The Oklahoma Medical Research Foundation is one step closer to beating rare forms of brain cancers.
OMRF brain tumor drug receives rare disease designations from the FDA
The drug treats fast-growing, deadly brain cancers with no effective treatment.
New use for OMRF brain cancer treatment could extend lives
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Oblato acquires all rights to glioblastoma drug from OMRF
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.